<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785885</url>
  </required_header>
  <id_info>
    <org_study_id>1651774</org_study_id>
    <nct_id>NCT04785885</nct_id>
  </id_info>
  <brief_title>Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery</brief_title>
  <acronym>ACTPOC</acronym>
  <official_title>Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficiency and promptness of heparin anticoagulation is necessary during the structural&#xD;
      heart procedures to minimize time from insertion of cannulae to valve deployment in cardiac&#xD;
      surgery. The goal of this study is to determine how rapidly the adequacy of heparin induced&#xD;
      anticoagulation occurs using two different point of care activated clotting time technologies&#xD;
      (iSTAT and Hemochron).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adequate anticoagulation is achieved in cardiac surgery and interventional cardiology&#xD;
      procedures with intravenous (IV) administration of unfractionated heparin. The Activated&#xD;
      clotting time (ACT) is routinely measured to assess adequacy of anticoagulation to prevent&#xD;
      clotting/thrombotic complications from placement of foreign materials used during cardiac&#xD;
      surgery and cardiology procedures. Alternative methods to measure adequacy of anticoagulation&#xD;
      such as measurement of Anti-Xa level and Reaction (R) time as assessed by&#xD;
      Thromboelastrography (TEG) have also been suggested. However, their use in clinical practice&#xD;
      is limited by lack of Point of Care (POC) technology and need for additional expertise to run&#xD;
      these tests.&#xD;
&#xD;
      The efficiency and promptness of heparin anticoagulation is necessary during the structural&#xD;
      heart procedures to minimize time from insertion of cannulae to valve deployment in cardiac&#xD;
      surgery. The time required to prevent major complications is on the order of seconds to&#xD;
      minutes. The goal of this study is to determine how rapidly the adequacy of heparin induced&#xD;
      anticoagulation occurs using two different point of care ACT technologies (iSTAT and&#xD;
      Hemochron). It is hypothesized that anticoagulation can be determined by the iSTAT ACT device&#xD;
      30 seconds after administration of heparin. Measuring heparin effectiveness at 30 or 90&#xD;
      seconds instead of the usual 3-minute time period may allow for earlier cardiac intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Activated Clotting Time (ACT)</measure>
    <time_frame>Baseline, 30 seconds and 180 seconds after IV heparin administration</time_frame>
    <description>Change in point of care activated clotting time (ACT) levels over time after IV heparin administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory-based anticoagulation</measure>
    <time_frame>Baseline, 30 seconds and 180 seconds after IV heparin administration</time_frame>
    <description>Laboratory-based anticoagulation measure of anti-Xa and TEG levels will be compared to point of care activated clotting time (ACT) levels.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <condition>Cardiac Valve Annuloplasty</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement</arm_group_label>
    <description>Patients receive 100U/Kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac Valve Annuloplasty</arm_group_label>
    <description>Patients receive 300U/kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>iStat Handheld Blood Analyzer</intervention_name>
    <description>An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.</description>
    <arm_group_label>Cardiac Valve Annuloplasty</arm_group_label>
    <arm_group_label>Transcatheter Aortic Valve Replacement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hemochron</intervention_name>
    <description>An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.</description>
    <arm_group_label>Cardiac Valve Annuloplasty</arm_group_label>
    <arm_group_label>Transcatheter Aortic Valve Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult cardiac surgical patients with intravenous (IV) administration of unfractionated&#xD;
        heparin.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult cardiac surgery patients presenting for elective valvular surgery&#xD;
&#xD;
          -  Interventional cardiology patients presenting elective Transcatheter Aortic Valve&#xD;
             Replacement (TAVR)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative IV heparin administration within 12 hours of surgery&#xD;
&#xD;
          -  Preoperative oral anticoagulant use within 24 hours of surgery&#xD;
&#xD;
          -  Platelet count &lt;120,000U/ml within 24 hours of surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Shyamal Asher, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital, Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyamal Asher, M.D.</last_name>
    <phone>(401) 444-5172</phone>
    <email>sasher@lifespan.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kendall, M.D.</last_name>
      <phone>401-444-4722</phone>
      <email>mark.kendall@lifespan.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Falter F, MacDonald S, Matthews C, Kemna E, Ca√±ameres J, Besser M. Evaluation of Point-of-Care ACT Coagulometers and Anti-Xa Activity During Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth. 2020 Nov;34(11):2921-2927. doi: 10.1053/j.jvca.2020.06.027. Epub 2020 Jun 12.</citation>
    <PMID>32620484</PMID>
  </reference>
  <reference>
    <citation>Bolliger D, Tanaka KA. Point-of-Care Coagulation Testing in Cardiac Surgery. Semin Thromb Hemost. 2017 Jun;43(4):386-396. doi: 10.1055/s-0037-1599153. Epub 2017 Mar 30. Review.</citation>
    <PMID>28359133</PMID>
  </reference>
  <reference>
    <citation>Heres EK, Speight K, Benckart D, Marquez J, Gravlee GP. The clinical onset of heparin is rapid. Anesth Analg. 2001 Jun;92(6):1391-5.</citation>
    <PMID>11375810</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

